בורטזומיב מדומי
medomie pharma ltd, israel - bortezomib - אבקה להכנת תמיסה לזריקה - bortezomib 3.5 mg/vial - bortezomib
בורטזומיב פרזניוס קבי 3.5 מג
neopharm (israel) 1996 ltd - bortezomib - אבקה להכנת תמיסה לזריקה - bortezomib 3.5 mg/vial - bortezomib
ולקייד 1 מ"ג
j-c health care ltd - bortezomib 1 mg - powder for solution for injection - bortezomib - velcade (bortezomib) for injection is indicated for the treatment of patients with multiple myeloma. velcade (bortezomib) for injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.
דארזלקס 20 מגמל תוך ורידי
j-c health care ltd - daratumumab - תרכיז להכנת תמיסה לאינפוזיה - daratumumab 20 mg / 1 ml - daratumumab
דארזלקס 120 מגמל תת עורי 1800 מג
j-c health care ltd - daratumumab - תמיסה להזרקה - daratumumab 120 mg / 1 ml - daratumumab
רבלימיד 5 מג
neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.
רבלימיד 5 מג
neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.
רבלימיד 10 מג
neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.
רבלימיד 10 מג
neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.
רבלימיד 15 מג
neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 15 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.